The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://www.voxmarkets.co.uk/rns/announcement/7a4ae1bb-59ed-44e3-bd14-5035baf97e23/
Positive update.
Https://www.investegate.co.uk/announcement/rns/aptamer-group--apta/trading-update/8191515
"The Group's current sales pipeline is strong, with over £3.0 million in advanced stage discussions. A proportion of these advanced stage deal negotiations is anticipated to progress through the laboratory before the end of the financial year. This anticipated deal value is in addition to the c.£1.4m of existing signed deals..."
"The Company looks forward to providing further updates on conversion of the pipeline to contracts before the year end"; this means more RNSs in the next 6 weeks (to June end).
The future is looking very promising.. patience is going to be rewarded.
I think it's gonna be too late for those waiting ("hoping"?) for a Placing at 0.50p , before they buy in - IMO
As I said last week, "SP will be over 1p in next 2-3 months" - but that might a bit too conservative an estimate!
100% agreed LTB....First stage ....the placing price of 1.1p.
Second.....into orbit. ...its coming!
A trading update with no new updates. It looks like Arron got his knuckles rapped for Friday's material/non-material tweet.
Yes, my thoughts exactly, his excitement got the better of him & he couldn’t help himself!
The Nomad got involved quickly.
The only thing that looks to different is £1.4m of signed deals at various stages of advancement as opposed to £1.3m at the Interims.
@ArgRich, I think there is one more difference - back on Feb 5th, it was:
"over £1.4 million of signed deals either being or to be processed through the laboratory. ....a pipeline of opportunities ...£2.0 million in medium-term deals. Approx £1.5 million of the medium-term deals are advanced stage....", so - IMO - a total of 2.9mln of signed/adv.stage deals;
Now, this has risen (in 3 months) to "... pipeline is strong, with OVER £3.0 million in advanced stage discussions", plus the 1.4mln of signed deals, meaning a 1.5 mln rise (min) in adv-stage deals; and we also assume that since Febr 5 (3 months ago) there has been ZERO processing of signed deals (which is not reasonable); here I mean that even thought the 1.4mln number is the same over 3 months, it can be the case that some of this has been processed (turning into REVENUES), and an equivalent amount has moved from the adv-stage deals' number to signed deals (IMO);
But the main plus from today is the comment that more contracts will be signed /announced in the next weeks (to June end).
LT why do you chose to ignore this from the interims, 28th March?
"The Company expects to progress the £1.3 million of signed work and a proportion of an additional £2.9 million of contracts in advanced-stage negotiations through the laboratory before the end of the financial year"
This shows £0.9m rise in pipeline between 5th Feb to 28th March and £0.1m increase between 28th March and today.
For reference, the pipeline was £11.7m on 21.03.23.
ARich, thanks for the additional numbers info. I chose the 5 Febr. one as I thought 3 months would provide a better comparison, but your numbers are also useful. The "discrepancies" are - just IMO - due to the fact that the numbers are dynamic, not static; for example if today I sign a deal, from the adn stage ones, it leaves the advanced stage total and becomes a signed one; also, when the signed one gets processed, it turns into revenues; I think the Co has not told us about Revenues since february, just signed deals and pipeline; this might explain the differences. But should I assume zero processing/revenues since February?
LT it pays to ignore any reference to pipeline or potential deals here and just concentrate on those signed, which still, as you rightly acknowledge, take a little time to convert to revenues.
As with all AIM/growing companies, they tend to emphasise positives rather than the harder realities (i.e. bank balance) which does sometimes make it harder to track where exactly things are financially.
We know from Arrons twitter chats that with the cash in hand and signed deals, they should have a runway until December with nothing new added.
Since February we only know that they've been working through their order book , but what the exact figures are only they know.
Everyone here knows the potential of APTA, it's just about the time taken/funds needed either raised or from trading in order to get there.
My guess (hope?) is that they will look to fundraise from a position of recently signed deal strength in the late summer/autumn.
Thanks AR. IMO (rather biased!), there will be no Placing this year as the cash - at end of Jan - sufficed to Aug-Sept, WITH NO SALES/INCOME from thereon (which is highly unlikely, given the 4.5 mln pipeline and signed deals so far); also, at any time from today until the Autumn, there could potentially be a licensing deal (up to 6-8 mln were mentioned 3 months ago); although this would be for the medium term, the impact would fall straight to Profit (i.e. no WCapital needed), plus there would be profile-raising, more approaches for business etc, so I hope a Placing would no be needed; we know (announced) that licensing deals could be close with the Top 5 and 15 Pharmas, also with Neuro-bio for the LTFs (within 2024, was mentioned in the Interims Presentation), plus NOVAVX has a licensing potential; plus others we may not know about.
All IMO.
Just to add that the IPO-Mkt cap of 80mln was mainly predicated on these licensing deals' potential, rather than the fee-for service; as we know, the Co run out of cash in the meantime and the edifice came down; however, the potential is still there, we just had a delay in execution.
GLA
A good run of pump now is the order of the day before discounted placing.
Only a few weeks left now, either cash has actually come into the bank on paid orders or it hasn’t.
The figures need to do the talking now, nothing else counts.
They can talk, talk talk about how great the POTENTIAL is and the size of the dollop of JAM but if all your business drops off and nobody is paying you its going to be one hell of a hard sell for further investment. Results in H1 were absolutely shocking.
Lets see what comes in as fully paid up, if its derisory again, SH will need to dig deep to keep it going.
Talking about "pump", I forgot to mention UNILEVER too (revenues in a couple of years, plus fee-for service until we get there); :)))))